Replies to post #131307 on Biotech Values

[biomaven0]

relapsed/refractory multiple myeloma, AML, ALL, and MDS, and blast phase or tyrosine kinase refractory CML

The only one of these I know much about is CML, from my research on Ariad. It does appear that one mode of resistant CML is via JAK activation, but the one article on this I read pointed to JAK3 as the culprit if I recall correctly. In any event, it would be a very small niche.

In AML, the JAK/STAT pathway is often activated, but it's not at all clear if this is via JAK or something else.

Bottom line is I think this is all pretty speculative, and from a valuation perspective is irrelevant compared with PV and ET.

Here's a free article (by the Incyte nemesis) focusing on a specific JAK2 activating mutation that may be helpful:

http://asheducationbook.hematologylibrary.org/content/2006/1/240.long

[NP1986]

Many were surprised at the price(not sure how given the recent trend), originally modeled around $40-60K/year.

Don't see why they were surprised. Management dropped several hints in recent months that pricing would probably exceed $60K/year.